Operating Segments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Summary of segmental information
Contract/Grant Revenue/Revenues, Principally from Grants	$ 2,787,709	$ 312,491	$ 5,116,554	$ 1,845,123
Income/ (Loss) from Operations	(5,141,378)	(1,860,662)	(8,427,118)	(5,704,443)
Amortization and Depreciation Expense	61,468	58,100	183,960	171,666
Other Income/(Expense), Net	791,823	(4,699,194)	(202,662)	(5,347,984)
Stock-Based Compensation	160,995	406,891	458,914	571,171
Identifiable Assets	6,272,942		6,272,942		8,265,455
Vaccines/BioDefense [Member]
Summary of segmental information
Contract/Grant Revenue/Revenues, Principally from Grants	2,729,854	264,920	4,928,284	1,683,265
Income/ (Loss) from Operations	545,728	(419,929)	949,032	(1,983,396)
Amortization and Depreciation Expense	9,922	28,316	29,666	83,951
Stock-Based Compensation	17,224	39,493	38,124	61,742
Identifiable Assets	1,566,050		1,566,050		1,870,414
BioTherapeutics [Member]
Summary of segmental information
Contract/Grant Revenue/Revenues, Principally from Grants	57,855	47,571	188,270	161,858
Income/ (Loss) from Operations	(4,855,765)	(1,080,436)	(6,541,832)	(2,068,703)
Amortization and Depreciation Expense	49,985	29,233	148,995	86,303
Stock-Based Compensation	33,118	158,142	142,374	205,083
Identifiable Assets	265,939		265,939		386,721
Corporate [Member]
Summary of segmental information
Income/ (Loss) from Operations	(831,341)	(360,297)	(2,834,318)	(1,652,344)
Amortization and Depreciation Expense	1,561	551	5,299	1,412
Other Income/(Expense), Net	791,823	(4,699,194)	(202,662)	(5,347,984)
Stock-Based Compensation	110,653	209,256	278,416	304,346
Identifiable Assets	$ 4,440,953		$ 4,440,953		$ 6,008,320